Ose Immunotherapeutics

Ose Immunotherapeutics est une entreprise française de biotechnologie dont le siège est à Nantes en France. Elle développe différents types d'immunothérapies.

Filings

142 filings

All Inside information96 Voting rights and capital15 Earnings release10 AGM documents8 Threshold crossing5 Share buyback4 Universal registration document3 Half-year financial report1

08/07/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
08/07/2026
Half-Year Report on Liquidity Contract with Invest Securities
Share buybackFR
05/06/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
04/06/2026
2025 Universal Registration Document
Universal registration documentZIP
03/06/2026
Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
AGM documentsFR
03/06/2026
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
Earnings releaseFR
28/05/2026
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
Inside informationFR
22/05/2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
Inside informationFR
06/05/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
30/04/2026
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
Earnings releaseFR
27/04/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
Inside informationFR
23/04/2026
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Inside informationFR
15/04/2026
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
Inside informationFR
14/04/2026
OSE Immunotherapeutics Evolves its Leadership Team
Inside informationFR
07/04/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
16/03/2026
OSE Immunotherapeutics Announces its 2026 Financial Calendar
Inside informationFR
10/03/2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
Inside informationFR
06/03/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
02/03/2026
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
Inside informationFR
26/02/2026
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Inside informationFR
29/01/2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
Inside informationFrench
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
Inside informationFR
20/01/2026
Half-Year Report on Liquidity Contract with Invest Securities
Inside information
09/12/2025
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
Inside informationFR
08/12/2025
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
Inside informationFR
17/11/2025
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
Inside informationFR
07/11/2025
OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines
Inside informationFR
03/11/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
30/10/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
16/10/2025
RAPPORT FINANCIER SEMESTRIEL 2025
Half-year financial reportFrench
15/10/2025
OSE Immunotherapeutics Reports First Half 2025 Financial Results
Earnings releaseFR
09/10/2025
Franchissement de seuils
Threshold crossingFrench
03/10/2025
Appointment of Marc Le Bozec as Interim CEO
Inside informationFR
02/10/2025
Franchissements de seuils
Threshold crossingFrench
30/09/2025
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
Inside informationFR
26/09/2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
Inside informationFR
25/09/2025
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
Inside informationFR
24/09/2025
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Inside informationFR
23/09/2025
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
Inside informationFR
22/09/2025
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
Inside informationFR
19/09/2025
Franchissements de seuils et déclaration d'intention
Threshold crossingFrench
16/09/2025
Déclaration d'intention
Threshold crossingFrench
12/09/2025
Mise à jour de l’information relative à l’Assemblée Générale du 30 septembre 2025-Constitution d’un pacte réunissant 61 actionnaires fondateurs, historiques, salariés et dirigeants de la Société portant sur environ 20,1% des droits de vote
Inside informationFrench
11/09/2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
Inside informationFR
09/09/2025
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
AGM documentsFR
08/09/2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
Inside informationFR
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
Inside information
02/09/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Voting rights and capitalFrench
29/08/2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
Inside informationFR

About

ISIN: FR0012127173
Ticker: OSE
LEI: 969500HIUWVGY6NZSM05
Sector: Health care
Founded: 2016
Country of registration: FR
Last filing: 08/07/2026, 18:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive